BR112022011414A2 - Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica - Google Patents

Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica

Info

Publication number
BR112022011414A2
BR112022011414A2 BR112022011414A BR112022011414A BR112022011414A2 BR 112022011414 A2 BR112022011414 A2 BR 112022011414A2 BR 112022011414 A BR112022011414 A BR 112022011414A BR 112022011414 A BR112022011414 A BR 112022011414A BR 112022011414 A2 BR112022011414 A2 BR 112022011414A2
Authority
BR
Brazil
Prior art keywords
protein
producing
heterodimeric
vector
nucleic acid
Prior art date
Application number
BR112022011414A
Other languages
English (en)
Inventor
Klatzmann David
Billiald Nicolas
Vazquez Thomas
Mariau Jérémie
Original Assignee
Iltoo Pharma
Inst Nat Sante Rech Med
Hopitaux Paris Assist Publique
Univ Sorbonne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iltoo Pharma, Inst Nat Sante Rech Med, Hopitaux Paris Assist Publique, Univ Sorbonne filed Critical Iltoo Pharma
Publication of BR112022011414A2 publication Critical patent/BR112022011414A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CONSTRUÇÃO QUIMÉRICA, PROTEÍNA HOMODIMÉRICA, PROTEÍNA HETERODIMÉRICA, ÁCIDO NUCLEICO, VETOR, CÉLULA HOSPEDEIRA, MÉTODOS PARA PRODUZIR UMA PROTEÍNA DIMÉRICA E PARA PRODUZIR UMA PROTEÍNA HETERODIMÉRICA. A presente invenção refere-se a uma construção quimérica compreendendo (i) uma porção interleucina 2 (IL2) e (ii) uma cadeia beta da proteína de ligação ao C4b (C4BPß) ou pelo menos um fragmento ou variante funcional da mesma que é capaz de formar uma proteína dimérica.3
BR112022011414A 2019-12-12 2020-12-11 Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica BR112022011414A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306637 2019-12-12
PCT/EP2020/085830 WO2021116444A1 (en) 2019-12-12 2020-12-11 Interleukin 2 chimeric constructs

Publications (1)

Publication Number Publication Date
BR112022011414A2 true BR112022011414A2 (pt) 2022-08-30

Family

ID=69232735

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011414A BR112022011414A2 (pt) 2019-12-12 2020-12-11 Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica

Country Status (12)

Country Link
US (1) US20230036793A1 (pt)
EP (1) EP4073094A1 (pt)
JP (1) JP2023505590A (pt)
KR (1) KR20220139293A (pt)
CN (1) CN115190885A (pt)
AU (1) AU2020401357A1 (pt)
BR (1) BR112022011414A2 (pt)
CA (1) CA3159468A1 (pt)
IL (1) IL293628A (pt)
MX (1) MX2022007203A (pt)
WO (1) WO2021116444A1 (pt)
ZA (1) ZA202206740B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4412631A1 (en) * 2021-10-06 2024-08-14 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
FR2869323B1 (fr) * 2004-04-22 2006-07-21 Univ Reims Champagne Ardenne Utilisation du gene codant la chaine beta de la proteine c4bp dans la production de proteines dimeriques recombinantes
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
US8437577B2 (en) 2009-03-05 2013-05-07 Tektronix, Inc. Methods and systems for image registration
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
SG10202010158TA (en) 2014-07-21 2020-11-27 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3364944B1 (en) 2015-10-22 2024-06-12 Iltoo Pharma Pharmaceutical compositions of il-2
KR20240115933A (ko) 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인

Also Published As

Publication number Publication date
KR20220139293A (ko) 2022-10-14
AU2020401357A1 (en) 2022-07-21
JP2023505590A (ja) 2023-02-09
CA3159468A1 (en) 2021-06-17
MX2022007203A (es) 2022-10-18
ZA202206740B (en) 2023-06-28
EP4073094A1 (en) 2022-10-19
CN115190885A (zh) 2022-10-14
WO2021116444A1 (en) 2021-06-17
IL293628A (en) 2022-08-01
US20230036793A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
BR112022011414A2 (pt) Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica
BR112016021572A2 (pt) Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
BR112022008415A2 (pt) Composições e métodos para substituição do dna codificado pelo rna dos alelos
Cha et al. Wnt5a and Wnt11 interact in a maternal Dkk1-regulated fashion to activate both canonical and non-canonical signaling in Xenopus axis formation
BR112017022086A2 (pt) anticorpos dirigidos contra o receptor de interleucina 36 (il-36r)
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
Baird et al. Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer
BRPI0517540A (pt) polipeptìdeo isolado, polinucleotìdeo isolado, construto de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir o polipeptìdeo e para melhorar o valor nutricional de uma ração animal, célula de planta, parte de planta ou planta transgênica, animal não-humano, transgênico, ou produtos, ou elementos do mesmo, uso de pelo menos um polipeptìdeo, aditivo de ração animal, e, composição de ração animal
PE20190911A1 (es) Composiciones y anticuerpos anti-lag-3
Kamei et al. Trehalase-2 protein contributes to trehalase activity enhanced by diapause hormone in developing ovaries of the silkworm, Bombyx mori
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
BR112021003313A8 (pt) Aditivo alimentar para gado, e preparações alimentares comreendendo tal aditivo alimentar
BR112022003241A2 (pt) Fontes de proteína não animal com propriedades fucionais
BR112013032914A2 (pt) forno contínuo com um transportador em cascata
BR112017017652A2 (pt) espaçador reforçado com fibra de vidro para unidade de vidro isolante
BR112022012324A2 (pt) Composições e métodos para modular simultaneamente expressão de genes
BR112021018793A2 (pt) Oligonucleotídeo modificado, composição farmacêutica compreendendo o mesmo composto para modular a expressão de dux4 e uso
BR112018071477A2 (pt) oligômeros antisenso e métodos de utilização dos mesmos para tratamento de doenças associadas com o gene da alfa-glicosidase ácida
BR112021020727A2 (pt) Materiais e métodos para produção de proteína
BR112022010786A2 (pt) Métodos de tratamento usando proteínas de ligação a ilt7
Cheng et al. The POU factor ventral veins lacking/drifter directs the timing of metamorphosis through ecdysteroid and juvenile hormone signaling
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112022010223A2 (pt) Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp)
BR112021026789A2 (pt) Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas
ECSP20076576A (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas